Regulus Therapeutics Inc. (RGLS) Short Interest Update
Regulus Therapeutics Inc. (NASDAQ:RGLS) was the target of a significant growth in short interest during the month of July. As of July 31st, there was short interest totalling 3,628,475 shares, a growth of 50.2% from the July 14th total of 2,416,318 shares. Based on an average daily trading volume, of 1,275,335 shares, the short-interest ratio is presently 2.8 days. Approximately 4.7% of the shares of the company are short sold.
A number of analysts recently issued reports on the stock. Needham & Company LLC restated a “hold” rating on shares of Regulus Therapeutics in a report on Wednesday, August 2nd. Chardan Capital downgraded shares of Regulus Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, August 2nd. Wedbush restated an “ourperform” rating and set a $4.00 price objective on shares of Regulus Therapeutics in a report on Monday. Zacks Investment Research downgraded shares of Regulus Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. Finally, BMO Capital Markets set a $1.00 price objective on shares of Regulus Therapeutics and gave the stock a “hold” rating in a report on Monday, June 12th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $3.58.
In related news, insider Joseph P. Hagan acquired 219,780 shares of the firm’s stock in a transaction that occurred on Tuesday, July 25th. The stock was acquired at an average price of $0.91 per share, for a total transaction of $199,999.80. Following the completion of the acquisition, the insider now owns 241,297 shares of the company’s stock, valued at approximately $219,580.27. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director William H. Rastetter acquired 274,725 shares of the firm’s stock in a transaction that occurred on Tuesday, July 25th. The shares were bought at an average price of $0.91 per share, with a total value of $249,999.75. The disclosure for this purchase can be found here. Insiders have purchased 549,450 shares of company stock valued at $500,000 in the last 90 days. 4.80% of the stock is currently owned by corporate insiders.
Several large investors have recently added to or reduced their stakes in RGLS. LMR Partners LLP acquired a new stake in Regulus Therapeutics during the second quarter valued at approximately $164,000. Wedbush Securities Inc. raised its stake in Regulus Therapeutics by 10.3% in the second quarter. Wedbush Securities Inc. now owns 199,521 shares of the biopharmaceutical company’s stock valued at $197,000 after buying an additional 18,600 shares during the last quarter. Tudor Investment Corp ET AL raised its stake in Regulus Therapeutics by 131.5% in the first quarter. Tudor Investment Corp ET AL now owns 108,061 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 61,373 shares during the last quarter. South Dakota Investment Council raised its stake in Regulus Therapeutics by 16.3% in the first quarter. South Dakota Investment Council now owns 1,327,058 shares of the biopharmaceutical company’s stock valued at $2,190,000 after buying an additional 186,130 shares during the last quarter. Finally, Wells Fargo & Company MN raised its stake in Regulus Therapeutics by 13.5% in the first quarter. Wells Fargo & Company MN now owns 782,380 shares of the biopharmaceutical company’s stock valued at $1,291,000 after buying an additional 93,295 shares during the last quarter. 21.09% of the stock is owned by hedge funds and other institutional investors.
Regulus Therapeutics (NASDAQ RGLS) opened at 0.8952 on Friday. Regulus Therapeutics has a 12 month low of $0.85 and a 12 month high of $3.68. The company’s market cap is $92.91 million. The firm’s 50-day moving average is $0.99 and its 200-day moving average is $1.30.
Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by $0.10. Regulus Therapeutics had a negative net margin of 31,460.47% and a negative return on equity of 173.20%. The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.02 million. On average, analysts anticipate that Regulus Therapeutics will post ($1.10) EPS for the current fiscal year.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.